related documents
- A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCICCTG MA. 21: Results of an interim analysis Conferences
- Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Conferences
- Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study. Conferences
- Correlation between 2 or 3 year (y) disease-free survival (DFS) and 5y overall survival (OS) in adjuvant systemic trials of early stage breast cancer. Conferences
- Evaluating the performance of risk assessment models in BRCA1 and BRCA2 mutation detection. Conferences
- The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Conferences
- Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Conferences